On May 1, 2026, the 5th Circuit Court of Appeals — the most conservative appellate court in America — issued a nationwide order in State of Louisiana et al. v. Food and Drug Administration that immediately blocked telehealth prescribing, pharmacy dispensing, and mail delivery of mifepristone across the entire United States. Not in one state. Not in red states. Everywhere. The drug used in more than two-thirds of all abortions in this country was effectively yanked from the modern healthcare system in a single ruling.
What the 5th Circuit Actually Did.
The ruling ordered the FDA to temporarily reimpose “in-person dispensing requirements” on mifepristone — restrictions that the FDA permanently removed in 2023 after reviewing decades of safety data confirming the drug is safe and effective. Under the 5th Circuit’s order, patients could no longer get mifepristone prescribed via telehealth. They couldn’t pick it up at a pharmacy. They couldn’t receive it by mail. They had to go to a certified prescriber’s office, in person, to get a drug that has been available by mail for years.
The practical effect was immediate and devastating. Telehealth abortion providers — the last bridge to care for millions of patients in states that haven’t banned abortion outright — shut down overnight. Some pivoted to prescribing only misoprostol, the second pill in the two-drug regimen, which can be used alone but is less effective. Others stopped operating entirely.
“Reimposing medically unnecessary in-person dispensing requirements for mifepristone will send shockwaves of chaos and confusion across the country and dramatically upend patients’ ability to obtain abortion care.” — Guttmacher Institute
The Backstory.
The lawsuit was filed by Louisiana, led by Attorney General Liz Murrill. The target: the FDA’s 2023 decision to remove the in-person dispensing requirement from mifepristone’s Risk Evaluation and Mitigation Strategy (REMS). Anti-abortion groups had urged the FDA, under Trump’s appointees, to conduct a new “safety review” of the drug — despite overwhelming evidence spanning 25 years and millions of patients showing mifepristone is remarkably safe.
In early April, a federal district court judge — Trump appointee David C. Joseph — actually paused the case to let the FDA finish its review. He acknowledged the FDA’s scientific expertise. That ruling, while sympathetic to Louisiana’s arguments, was a temporary reprieve. Louisiana’s plaintiffs immediately appealed to the 5th Circuit, which overruled the district court and imposed the in-person requirement on the entire country.
In 2024, the Supreme Court unanimously rejected a similar challenge to mifepristone in FDA v. Alliance for Hippocratic Medicine. The Court ruled that the plaintiff doctors lacked legal standing to challenge the FDA’s regulation. So the anti-abortion movement found a new plaintiff with standing: a state government. Louisiana stepped up. Same goal, new vehicle.
Alito Issues the Stay. Yes, That Alito.
On May 4, Justice Samuel Alito — the author of the Dobbs decision that overturned Roe v. Wade — issued an administrative stay of the 5th Circuit’s order. The stay restores access to telehealth prescribing, mail delivery, and pharmacy dispensing of mifepristone. For now.
Alito did not explain his decision. He gave Louisiana until May 7 to respond to the emergency appeals filed by Danco and GenBioPro, the two companies that manufacture mifepristone. The stay expires May 11, when the full Court is expected to act.
The pharmaceutical companies argued that the Supreme Court must intervene to prevent “regulatory chaos,” calling the 5th Circuit’s ruling “deeply unsettling to drug sponsors, healthcare providers, patients, and the public — all of whom rely on FDA’s exercise of scientific judgment and orderly administration of the Nation’s complex system of drug regulation.”
What’s Really at Stake.
Mifepristone is used in more than two-thirds of all abortions in the United States. Telehealth prescribing has become the primary way patients in states with abortion protections access the drug — and the main way patients in ban states circumvent those bans. Ending telehealth prescribing and mail delivery doesn’t just affect red states. It affects every state. That’s the point.
Louisiana AG Liz Murrill said the 5th Circuit ruling defended her state’s sovereignty and the safety of its residents. In other words: Louisiana wants to control what happens inside other states’ borders. A state that has banned abortion is using the federal courts to make it harder for patients in New York, California, and Illinois to access a legal medical procedure.
The Trump administration’s FDA, meanwhile, has been notably silent. It asked the district court to pause the case so it could complete a “safety review” — a review that anti-abortion groups requested and that contradicts the existing scientific consensus. The FDA hasn’t reacted to the 5th Circuit’s ruling or the SCOTUS stay.
“Telehealth has been the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned.” — Nancy Northup, Center for Reproductive Rights
The Timeline.
May 1: 5th Circuit issues nationwide order blocking telehealth/mail mifepristone. Takes effect immediately. Providers begin shutting down. May 4: SCOTUS — Justice Alito — issues administrative stay restoring access. May 7: Louisiana’s response deadline. May 11: Alito’s stay expires. Full Court expected to act. If the Court declines to extend the stay, the 5th Circuit’s order snaps back into effect nationwide.
One week. That’s how long abortion access in America has been guaranteed. One week at a time, by emergency order, from the justice who killed Roe.
Alexis McGill Johnson, president of Planned Parenthood Action Fund: “While mifepristone access returns to where it was on Friday morning, the whiplash and chaos that patients and providers are navigating have already had real consequences for real peoples’ lives and futures.”
The Court will decide by May 11. The question is whether six justices — the same ones who overturned Roe — will let a single appellate court functionally ban the most common method of abortion in America. Again.
Sources.
- Politico: Supreme Court restores abortion pill access — for now — May 4, 2026. Alito administrative stay details. Louisiana until May 7 to respond. Stay expires May 11. Telehealth providers paused services after 5th Circuit ruling. Some pivoted to misoprostol only.
- ABC News: Supreme Court restores access to mail-order abortion pill mifepristone, for now — May 4, 2026. Alito did not explain decision. Mifepristone used in more than two-thirds of abortions. Telehealth prescribing restored temporarily. FDA approved in-person removal in 2023.
- ABC News: Appeals court issues nationwide order blocking telehealth distribution of abortion pill mifepristone — May 1, 2026. 5th Circuit order takes effect immediately. Louisiana AG Murrill statement. 2024 Supreme Court ruling on standing referenced. Nancy Northup quote.
- Guttmacher Institute: US Supreme Court Blocks Fifth Circuit Decision on Mifepristone — May 4, 2026. Stay extends to May 11. Full court expected to rule on whether in-person dispensing can be reimposed while case proceeds. End goal: eliminate telehealth and pharmacy dispensing nationwide.
- Guttmacher Institute: Fifth Circuit Decision Directs FDA to Restrict Mifepristone Access — May 1, 2026. 5th Circuit orders FDA to reimpose REMS in-person dispensing requirements. Alexis McGill Johnson quote. 25+ years of safety data. “Shockwaves of chaos and confusion.”
- Center for Reproductive Rights: 5th Circuit Limits Telehealth Provision of Abortion Pill — May 1, 2026. Lower court had stayed the case; 5th Circuit overruled. FDA removed in-person requirement in 2023. Louisiana as lead plaintiff.
- NPR/New Hampshire Public Radio: Telehealth abortion will remain available for now — April 7, 2026. Background on district court Judge David C. Joseph’s ruling pausing the case. Trump appointee acknowledged FDA expertise. 1 in 4 abortions via telehealth. Trump FDA signaling harder line.